DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: rizatriptan benzoate

Summary for Generic Name: rizatriptan benzoate

Tradenames:3
Patents:1
Applicants:13
NDAs:20
Drug Master File Entries: see list21
Suppliers: see list6
Therapeutic Class:Antimigraine Agents

Pharmacology for Ingredient: rizatriptan benzoate

Clinical Trials for: rizatriptan benzoate

Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1)
Status: Completed Condition: Migraine Disorders

Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)
Status: Completed Condition: Migraine Disorders

Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)
Status: Completed Condition: Migraine Headache

A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)
Status: Completed Condition: Migraine, Acute

Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops
Status: Recruiting Condition: Chronic Post-traumatic Headache

MK0462 in Treatment of Migraine With Recurrence (MK0462-022)
Status: Completed Condition: Migraine Headache

A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)
Status: Completed Condition: Acute Migraine With or Without Aura in Adolescents

Two Rizatriptan Prescribing Portions for Treatment of Migraine
Status: Completed Condition: Migraine

Maxalt 10mg Plus Caffeine 75mg in the Acute Treatment of Migraine Headache
Status: Completed Condition: Migraine With Aura; Migraine Without Aura

MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)
Status: Completed Condition: Migraine Headache

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Merck
MAXALT-MLT
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865Jun 29, 1998RXNo5,457,895*PED<disabled>Y
Merck
MAXALT-MLT
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865Jun 29, 1998RXNo<disabled>NEW PATIENT POPULATION
Merck
MAXALT-MLT
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865Jun 29, 1998RXNo<disabled>PEDIATRIC EXCLUSIVITY
Merck
MAXALT-MLT
rizatriptan benzoate
TABLET, ORALLY DISINTEGRATING;ORAL020865Jun 29, 1998RXYes5,457,895*PED<disabled>Y
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc